Sun Pharmaceuticals initiates recall for anti-allergic Loratadine in U.S.

11/01/2015 // JusticeNewsFlash // (press release)

Mumbai – India based pharmaceutical company Sun Pharmaceuticals has voluntarily initiated a recall on its anti-allergic drug Loratadine in the U.S. Business Standard reported that the recall involves more than one million boxes of the medication that were manufactured and distributed by Ohm Laboratories, which is based in New Jersey.


The company is a subsidiary of Ranbaxy, which was acquired by Sun Pharmaceuticals in 2014 as part of a $4 billion agreement. The deal made Sun Pharmaceuticals the largest Indian pharma by sales.

The recall was announced after checks showed the tablets to be “out of specification” and “super potent.” It has been classified as a Class III recall, which means that the use of a violative product or exposure to it will not likely lead to adverse health issues.

Details about the Loratadine recall have been outlined by the U.S. Food and Drug Administration on the agency’s website.


To read more about Product Recalls on Justice News Flash follow our Product Recall News


More stories related to Product Recalls at /?s=product+recalls


Source: Business Standard News Story  

#JusticeNewsFlash #ProductRecallNews

Media Information:

Phone: 866-598-1315